ContextVision Drives Medical Image Enhancement Innovation

 Medical Technology Software Company Celebrates Year of Product Expansion and Internal Growth

STOCKHOLM – December 02, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announces a progressive year of product innovation and talent acquisition. The company will virtually display its latest advancements in image enhancement as well as introduce new key staff to attendees of RSNA 2020.

Medical Imaging – The release of Rivent, ContextVision’s seventh generation of image enhancement software for 2D ultrasound, was a significant milestone, providing next-level image quality and stronger processing capabilities while retaining a natural look. Addressing the growing need for clearer images and greater value of ultrasound, Rivent provides well defined borders, clear tissue differentiation, and functions for automatic image quality optimization.

Digital Pathology – ContextVision became a first mover in the rapidly growing digital pathology market with the release of its latest product, INIFY Prostate Screening, a powerful AI-based software that automatically predicts, outlines and quantifies suspicious cancer areas. This investment was a strategic step to capitalizing on the opportunities presented from ongoing efforts toward digitalization.

Talent Acquisition – The company also prioritized growing its organization, announcing strategic new hires, including:

  • Ola Lindblad, VP of Medical Imaging – With more than 20 years of experience in the global software industry, Lindblad is driving the company’s success across new and existing regions.
  • Arto Järvinen, CTO – Järvinen, recently promoted to CTO, has been Director of R&D since 2011 and is instrumental in leading the company’s strategic R&D work.
  • Magnus Aurell, VP of Digital Pathology – Aurell has more than 25 years of experience from senior management positions in technology companies in the medical field. He is developing ContextVision’s pathology business unit and is a key member of the management team.
  • Dr. Martin Ingvar, board member – Dr. Ingvar is newly added to ContextVision’s board of directors. As Professor in Integrative Medicine at Karolinska Institute and founding member of ICHOM, Dr. Ingvar brings a unique mix of clinical experience and a strong vision for how healthcare services may be delivered in the future.

“2020 has been a progressive year for ContextVision. We are proud to be leading medical imaging and digital pathology innovation and look forward to an exciting RSNA,” said Fredrik Palm, CEO. “In addition to strategic product initiatives, we have strengthened the organization with key internal resources who will be instrumental in further driving product development and sales. I’m proud of our achievements over the past year and look forward to continue delivering on our promise to contribute to advanced patient care in the years ahead.”

ContextVision invites RSNA 2020 attendees to learn more about these latest advancements in medical imaging and book a meeting with a company representative at their virtual booth here.

Not registered to attend RSNA? Get in touch with ContextVision at

About ContextVision

ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.

Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment.

ContextVision is now entering the fast-growing digital pathology market. We are re-investing significantly in our product portfolio of decision support tools and we are dedicated to becoming a leading resource for pathologists to radically develop cancer diagnosis and improve patient care.

The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.